On May 31, 2021, Reliable Medical Technology CO.,Ltd. (hereinafter referred to as "Reliable Med") issued an announcement announcing that the company had recently completed A+ round of financing of tens of millions of yuan.

It is reported that on December 18, 2020, Reliable Med had completed tens of millions of yuan in A round financing. Within 6 months, Reliable Med completed 2 rounds of financing.

Founded in 2019, Reliable Med is an IVD enterprise dedicated to the research, development, production and sales of clinical mass spectrometry equipment and supporting kits. Reliable Med provides clinical medicine customers with mass spectrometer devices, automated supporting equipment, in vitro diagnostic kits and a one-stop integrated solution of application methodology and services.

As a platform company in the field of clinical mass spectrometry, Reliable Med has a very complete pipeline of mass spectrometry products, including inductively coupled plasma-mass spectrometer (ICP-MS), gas chromatography-mass spectrometer (GC-MS), liquid chromatography-tandem mass spectrometer (LC-MS/MS) three categories of mass spectrometry platforms, as well as supporting automated pretreatment equipment and detection kits.

In recent years, the continuous maturity of clinical market awareness of mass spectrometry technology and the increasing surge of testing demands have promoted the continuous investment of mass spectrometry instrument technology and its supporting kits in relevant fields in China, which has greatly promoted the localization process of clinical mass spectrometry and reversed the unfavorable situation that the core equipment is under the control of others for a long time.

April 23, 2021, Reliable Med launched the original research trace element analyzer Inspector SQ60 based on the principle of mass spectrometry (using the international advanced inductively coupled plasma mass spectrometry technology) products obtained the "Medical Device Registration Certificate of the People's Republic of China" issued by ZheJiang Medical Products Administration. It has opened a new chapter in the application of clinical mass spectrometry to trace element detection in China.

In order to improve the level of clinical laboratory management, biological safety, reliability of results, and save human resources and medical costs, it is urgent to develop an efficient and high-quality clinical mass spectrometry pipeline. According to Yi Zheng, the founder of Reliable Med, the next-generation trace element analysis platform, the modular assembly line system for clinical mass spectrometry, has been put into research and development and is expected to be available next year.